Merck begins investigation into its handling of Vioxx

Share this article:
Directors at Merck are investigating the company's actions prior to its voluntary withdrawal of Vioxx from the market in September.
Merck's board of directors appointed a special committee comprised of seven members to closely examine the company's actions and respond to shareholder litigation, the company said in a statement yesterday.
William Bowen, president of The Andrew Mellon Foundation, will chair the special committee, which has hired the law firm Debevoise & Plimpton to conduct the review.
John Martin, a lawyer at Debevoise & Plimpton leading the inquiry, told the New York Times the committee wanted an independent examination of Merck's actions. Lawyers will review internal documents and interview company executives, he said.
"Our job is to conduct an investigation and not to defend the company," Martin told the Times.
Merck's chief executive, Raymond Gilmartin said the committee would have the "complete" cooperation of Merck management and full resources to make its assessment.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.